Onglyza and Kombiglyze XR are two medications designed to solve the same problem: out-of-control blood sugar in patients who have been diagnosed with Type 2 diabetes without diabetic ketoacidosis. Both products are manufactured by the drug company Astra Zeneca, which has marketed them as effectively controlling blood sugar without causing weight gain as other diabetes medications can do. Unfortunately, both have been linked to a number of serious and even deadly side effects. If you have been negatively impacted by either of these medications, the attorneys at Danziger & De Llano can help.
How do Onglyza and Kombiglyze XR Work?
Astra Zeneca received U.S. Food and Drug Administration approval for Onglyza in 2009, and for Kombiglyze XR in the following year. The main ingredient in both drugs is saxagliptin: the difference between the two is that Kombiglyze XR also contains metformin HCl, which makes it an extended-release drug. Both drugs have been extremely popular and it has been anticipated that their sales for the drug company will easily surpass $2 billion next year.
They work by inhibiting an enzyme that breaks down an incretin hormone that normally signals the pancreas to make insulin after a meal. Because people with diabetes make less of this hormone, their body ends up with too much sugar in their bloodstream: by stopping the hormone, the body can make the insulin that it needs. Unfortunately, the medication can also lead to heart failure, pancreatic and thyroid cancer, and pancreatitis.
If you or someone you love was prescribed Onglyza or Kombiglyze XR and have suffered any of these serious adverse effects, you need a dedicated attorney who can stand up to the drug companies and get you the compensation you deserve. At Danziger & De Llano, we are committed to fighting for your rights. Contact us today at 1-866-222-9990.
Adverse Side Effects of Onglyza and Kombiglyze XR
Like most medications, the labeling on packages of Onglyza and Kombiglyze XR contains warnings about common side effects, which can include skin reaction, fluid retention, joint pain, and inflammation. It also lists pancreatitis and heart failure as potential serious side effects, and the higher risk of these are of particular concern. Alinical trial conducted a few years after the medication was released to determine whether it also provided heart-protecting benefits revealed the exact opposite: there was a link between Onglyza and a 27 percent increase in hospitalization for cardiac failure. This led to physicians advising that those at risk for heart failure should not be taking the drug.
One of the biggest concerns about the use of Onglyza and Kombiglyze XR is their potential link to an increased risk of pancreatic cancer. Patients with diabetes 2 have a reduced number of the pancreatic beta cells that secrete insulin. Though Onglyza and Komgiblyze XR both increase the number of those cells, as well as their size, the newly formed calls are irregular. Patients also formed a specific type of tumor that, though benign, can later become cancerous.
Pancreatitis is inflammation of the pancreas that can require hospitalization, and can even lead to death.
The risk of heart failure, severe joint pain, pancreatitis and pancreatic pre-cancers were all communicated by the Food and Drug Administration years after the drug was released onto the market. This means that if you took the drug prior to the issuance of these warnings, you had no way of knowing of their dangers.
Drug companies have an obligation to thoroughly test all medications before releasing them onto the market. Doing so protects consumers from serious and potentially deadly side effects: failure to do so often represents negligence and leads to irreparable damage and suffering. If you or someone you love has been harmed as a result of having taken Astra Zeneca’s Onglyza or Kombiglyze XR, the attorneys at Danziger & De Llano are here to help.